Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 5/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995400 | 0.88 | MEN1 (0.50) | POLBMEN1KMT2ATHRBTP53 | |
| SCHEMBL5926281 | 0.87 | TACR3 (0.53) | CYP26A1TACR3CTSAUTS2R | |
| SCHEMBL3989390 | 0.83 | TACR3 (0.44) | THRBTP53TACR3CTSAFADS1 | |
| SCHEMBL3972848 | 0.83 | POLB (0.53) | POLBMEN1KMT2ATACR3CTSA | |
| SCHEMBL5926521 | 0.80 | SERPINE1 (0.41) | MEN1KMT2ATHRBTP53CYP26A1 | |
| SCHEMBL3979330 | 0.80 | POLB (0.43) | POLBMEN1KMT2ATHRBTP53 | |
| SCHEMBL3993040 | 0.80 | ALDH1A1 (0.43) | POLBMEN1KMT2ATHRBTP53 | |
| SCHEMBL5926851 | 0.80 | TACR3 (0.44) | THRBTP53CYP26A1TACR3CTSA | |
| SCHEMBL3979415 | 0.80 | TACR3 (0.44) | THRBTP53CYP26A1TACR3CTSA | |
| SCHEMBL6503530 | 0.79 | DCAF1 (0.45) | TACR3CTSAALDH1A1UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | POLB 3571/4885MEN1 1372/4885KMT2A 3655/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | POLB 3935/4885MEN1 3448/4885KMT2A 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.